Bayer AG
XETRA:BAYN
Intrinsic Value
The intrinsic value of one
BAYN
stock under the Base Case scenario is
93.7
EUR.
Compared to the current market price of 58.19 EUR,
Bayer AG
is
Undervalued by 38%.
The Intrinsic Value is calculated as the average of the two valuation methods:
Fundamental Analysis
BAYN Profitability Score
Profitability Due Diligence
Bayer AG's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
Score
Bayer AG's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
BAYN Solvency Score
Solvency Due Diligence
Bayer AG's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Score
Bayer AG's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Balance Sheet Decomposition
Bayer AG
BAYN Capital Structure
Bayer AG
| Market Capitalization | 57.2B EUR | |
| Total Debt | 39.5B EUR | |
| Minority Interest | 195M EUR | |
| Preferred Equity | 0 EUR | |
| Cash and Equivalents | 4.4B EUR | |
| Short-Term Investments | 4.7B EUR | |
| Enterprise Value | 87.7B EUR | |
Wall St
Price Targets
BAYN Price Targets Summary
Bayer AG
According to Wall Street analysts, the average 1-year price target for
BAYN
is 76.46 EUR
with a low forecast of 54.54 EUR and a high forecast of 111.3 EUR.
Competitive Landscape
BAYN Competitors
Bayer AG
BAYN Suppliers & Customers
Bayer AG
Bayer AG has 111 key suppliers from 11 countries and 20 industries. The majority of these suppliers are located in the United States of America, with the largest number of suppliers in the Biotechnology industry.
Bayer AG has 43 key customers from 8 countries and 7 industries. The majority of these customers are located in the United States of America, with the largest number of customers in the Biotechnology industry.
Shareholder Return
BAYN Price
Bayer AG
| Average Annual Return | -9.57% |
| Standard Deviation of Annual Returns | 28.78% |
| Max Drawdown | -56% |
| Market Capitalization | 57.2B EUR |
| Shares Outstanding | 982 424 100 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Bayer AG
Country
Industry
Market Cap
Dividend Yield
Description
Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. The company is headquartered in Leverkusen, Nordrhein-Westfalen and currently employs 99,637 full-time employees. The firm's segments are Pharmaceuticals, Consumer Health, Crop Science. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and ophthalmology, as well as radiopharmacology and others. The firm is focusing on their oncology platform for Targeted Alpha Therapies for treating prostate cancer. The Consumer Health segment develops, produces and markets nonprescription over-the-counter products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories, among others. The Crop Science segment researches, develops and markets crop protection solutions and seeds.
Contact
IPO
Employees
Officers
The intrinsic value of one
BAYN
stock under the Base Case scenario is
93.7
EUR.
Compared to the current market price of 58.19 EUR, Bayer AG is Undervalued by 38%.
